Metabolic bariatric surgery in face of new anti-obesity medications-10 + 1 challenges

References

[1] Apovian CM.Obesity is a disease!.Curr Opin Endocrinol Diabetes Obes2013;20:367-8

[2] Bray GA,Wilding JPH.World Obesity FederationObesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation.Obes Rev2017;18:715-23

[3] De Lorenzo A, Gratteri S, Gualtieri P, Cammarano A, Bertucci P, Di Renzo L. Why primary obesity is a disease?.J Transl Med2019;17:169 PMCID:PMC6530037

[4] Christensen S.Recognizing obesity as a disease.J Am Assoc Nurse Pract2020;32:497-503

[5] Scully JL.What is a disease?.EMBO Rep2004;5:650-3 PMCID:PMC1299105

[6] Dr. Sharma’s obesity notes. The M & Ms of obesity assessment. Available from: https://www.drsharma.ca/sharma-mnemonic-the-m-ms-of-obesity-assessment [Last accessed on 13 Oct 2023].

[7] Gill MG.Metabolic associated fatty liver disease: addressing a new era in liver transplantation.World J Hepatol2020;12:1168-81 PMCID:PMC7772736

[8] Lauby-Secretan B,Loomis D,Bianchini F.International Agency for Research on Cancer Handbook Working GroupBody fatness and cancer--viewpoint of the IARC Working Group.N Engl J Med2016;375:794-8. PMCID:PMC6754861

[9] Patel AV,Teras LR.Excess body fatness and cancer risk: a summary of the epidemiologic evidence.Surg Obes Relat Dis2023;19:742-5.

[10] Rosen H.Is obesity a disease or a behavior abnormality? Did the AMA get it right?.Mo Med2014;111:104-8 PMCID:PMC6179496

[11] Kyle TK,Allison DB.Regarding obesity as a disease: evolving policies and their implications.Endocrinol Metab Clin North Am2016;45:511-20. PMCID:PMC4988332

[12] Salas XR, Hussey B.'Body size is not a choice' and deserves legal protections. Available from: https://www.medscape.com/viewarticle/993780 [Last accessed on 13 Oct 2023]

[13] Sjöström L.Review of the key results from the Swedish Obese Subjects (SOS) trial-a prospective controlled intervention study of bariatric surgery.J Intern Med2013;273:219-34

[14] Courcoulas AP,Neiberg RH.Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment: a randomized clinical trial.JAMA Surg2015;150:931-40 PMCID:PMC4905566

[15] Schauer PR,Kirwan JP.STAMPEDE InvestigatorsBariatric surgery versus intensive medical therapy for diabetes-5-year outcomes.N Engl J Med2017;376:641-51 PMCID:PMC5451258

[16] Aminian A,Wilson R.Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis.JAMA2021;326:2031-42 PMCID:PMC8587225

[17] Mingrone G,De Gaetano A.Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial.Lancet2021;397:293-304.

[18] Chakhtoura M,Ghezzawi M,Tcheroyan R.Pharmacotherapy of obesity: an update on the available medications and drugs under investigation.EClinicalMedicine2023;58:101882 PMCID:PMC10041469

[19] Ahima RS.The health risk of obesity--better metrics imperative.Science2013;341:856-8

[20] Moore EC.The BMI: is it time to scratch for a more accurate assessment of metabolic dysfunction?.Curr Obes Rep2014;3:286-90

[21] Hudda MT,Donin AS.Reassessing ethnic differences in mean BMI and changes between 2007 and 2013 in English children.Obesity2018;26:412-9. PMCID:PMC5814928

[22] Laine C.Overweight and obesity: current clinical challenges.Ann Intern Med2023;176:699-700

[23] Eisenberg D,Aarts E.2022 American Society for metabolic and bariatric surgery (ASMBS) and international federation for the surgery of obesity and metabolic disorders (IFSO): indications for metabolic and bariatric surgery.Surg Obes Relat Dis2022;18:1345-56

[24] Brethauer SA, el Chaar M.Standardized outcomes reporting in metabolic and bariatric surgery.Surg Obes Relat Dis2015;11:489-506

[25] Avery A,Harrington M.Setting targets leads to greater long-term weight losses and 'unrealistic' targets increase the effect in a large community-based commercial weight management group.J Hum Nutr Diet2016;29:687-96. PMCID:PMC5111772

[26] Grover BT,Kothari SN,Kallies KJ.Defining weight loss after bariatric surgery: a call for standardization.Obes Surg2019;29:3493-9.

[27] Peterli R,Peters T.Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial.JAMA2018;319:255-65. PMCID:PMC5833546

[28] Salminen P,Ovaska J.Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial.JAMA2018;319:241-54. PMCID:PMC5833550

[29] Salminen P,Helmiö M.Effect of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass on weight loss, comorbidities, and reflux at 10 years in adult patients with obesity: the SLEEVEPASS randomized clinical trial.JAMA Surg2022;157:656-66 PMCID:PMC9218929

[30] O'Brien PE,Brennan L.Long-term outcomes after bariatric surgery: a systematic review and meta-analysis of weight loss at 10 or more years for all bariatric procedures and a single-centre review of 20-year outcomes after adjustable gastric banding.Obes Surg2019;29:3-14 PMCID:PMC6320354

[31] Azagury D,Hamdallah I,Kim J.ASMBS position statement on medium- and long-term durability of weight loss and diabetic outcomes after conventional stapled bariatric procedures.Surg Obes Relat Dis2018;14:1425-41.

[32] Thaher O,Driouch J.Long- and short-term outcomes of bariatric surgery in 7755 patients with obesity and comorbidities.Minerva Surg2023;78:145-54.

[33] Neuberg M,Gignoux B.Long-term outcomes after one-anastomosis gastric bypass (OAGB) in morbidly obese patients.Obes Surg2020;30:1379-84

[34] Carandina S,Zulian V.Long-term results of one anastomosis gastric bypass: a single center experience with a minimum follow-up of 10 years.Obes Surg2021;31:3468-75

[35] Sánchez-Pernaute A,Ferré NP.Long-term results of single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S).Obes Surg2022;32:682-9 PMCID:PMC8760573

[36] Soong TC,Lee WJ.Long-term efficacy of bariatric surgery for the treatment of super-obesity: comparison of SG, RYGB, and OAGB.Obes Surg2021;31:3391-9

[37] Musella M,Velotti N,Vitiello A.Ten-year results of laparoscopic sleeve gastrectomy: retrospective matched comparison with laparoscopic adjustable gastric banding-is there a significant difference in long term?.Obes Surg2021;31:5267-74 PMCID:PMC8595233

[38] Vital R,Gunes S.Long-term outcomes 10 years after laparoscopic sleeve gastrectomy: a single center retrospective analysis.Obes Surg2023;33:2356-60.

[39] El Ansari W, Elhag W. Weight regain and insufficient weight loss after bariatric surgery: definitions, prevalence, mechanisms, predictors, prevention and management strategies, and knowledge gaps-a scoping review.Obes Surg2021;31:1755-66. PMCID:PMC8012333

[40] Montastier E,Tuyeras G.Long-term nutritional follow-up post bariatric surgery.Curr Opin Clin Nutr Metab Care2018;21:388-93.

[41] Mears R,Pournaras DJ.Bariatric surgery: the GP's role in long-term post-bariatric surgery follow-up.Br J Gen Pract2021;71:248-9. PMCID:PMC8163465

[42] Chandarana K.Shedding pounds after going under the knife: metabolic insights from cutting the gut.Nat Med2012;18:668-9

[43] Sanches E,Topal B.Cardiac remodeling in obesity and after bariatric and metabolic surgery; is there a role for gastro-intestinal hormones?.Expert Rev Cardiovasc Ther2019;17:771-90

[44] Timmermans M,Sanches EE.The effects of glucagon like peptide-1 (GLP-1) on cardiac remodeling: exploring the role of medication and physiological modulation after metabolic surgery.Minerva Endocrinol2022;47:449-59.

[45] Holst JJ.Glucagon-like peptide-1: Are its roles as endogenous hormone and therapeutic wizard congruent?.J Intern Med2022;291:557-73

[46] Sista F,Clementi M,Cecilia M.The effect of sleeve gastrectomy on GLP-1 secretion and gastric emptying: a prospective study.Surg Obes Relat Dis2017;13:7-14

[47] McCarty TR,Thompson CC.Effect of sleeve gastrectomy on ghrelin, GLP-1, PYY, and GIP gut hormones: a systematic review and meta-analysis.Ann Surg2020;272:72-80

[48] Jirapinyo P,Qazi T,Thompson CC.A meta-analysis of GLP-1 after roux-en-y gastric bypass: impact of surgical technique and measurement strategy.Obes Surg2018;28:615-26

[49] Schneider R,Peterli R.GLP-1 analogues as a complementary therapy in patients after metabolic surgery: a systematic review and qualitative synthesis.Obes Surg2020;30:3561-9

[50] Gabery S,Paulsen SJ.Semaglutide lowers body weight in rodents via distributed neural pathways.JCI Insight2020;5:133429 PMCID:PMC7213778

[51] Pi-Sunyer X,Fujioka K.SCALE Obesity and Prediabetes NN8022-1839 Study GroupA randomized, controlled trial of 3.0 mg of liraglutide in weight management.N Engl J Med2015;373:11-22

[52] Davies MJ,Bode B.NN8022-1922 Study GroupEfficacy of liraglutide for weight loss among patients with type 2 diabetes: the scale diabetes randomized clinical trial.JAMA2015;314:687-99

[53] le Roux CW, Astrup A, Fujioka K, et al; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.Lancet2017;389:1399-409

[54] Davies M,Jeppesen OK.STEP 2 Study GroupSemaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.Lancet2021;397:971-84

[55] Wilding JPH,Calanna S.STEP 1 Study GroupOnce-weekly semaglutide in adults with overweight or obesity.N Engl J Med2021;384:989-1002.

[56] Wadden TA,Billings LK.STEP 3 investigatorseffect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial.JAMA2021;325:1403-13 PMCID:PMC7905697

[57] Rubino D,Davies M.STEP 4 InvestigatorsEffect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial.JAMA2021;325:1414-25 PMCID:PMC7988425

[58] Garvey WT,Bhatta M.STEP 5 Study GroupTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.Nat Med2022;28:2083-91 PMCID:PMC9556320

[59] Iqbal J,Hu N.Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.Obes Rev2022;23:e13435.

[60] Guo X,Lyu X.The antiobesity effect and safety of GLP-1 receptor agonist in overweight/obese patients without diabetes: a systematic review and meta-analysis.Horm Metab Res2022;54:458-71

[61] Garvey WT,Jastreboff AM.SURMOUNT-2 investigatorsTirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.Lancet2023;402:613-26

[62] Jastreboff AM,Ahmad NN.SURMOUNT-1 InvestigatorsTirzepatide once weekly for the treatment of obesity.N Engl J Med2022;387:205-16.

[63] Frías JP,Rosenstock J.SURPASS-2 InvestigatorsTirzepatide versus semaglutide once weekly in patients with type 2 diabetes.N Engl J Med2021;385:503-15

[64] ‘Staggering’ weight loss with tirzepatide. Available from: https://desang.net/2023/07/staggering-weight-loss-with-tirzepatide/ [Last accessed on 13 Oct 2023]

[65] Alkhezi OS,Alfayez OM,Almutairi AR.Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials.Obes Rev2023;24:e13543

[66] Cotugno M,Saldalamacchia G.Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: a 12-month retrospective evaluation.Acta Diabetol2015;52:331-6

[67] Capristo E,De Gaetano A.Intensive lifestyle modifications with or without liraglutide 3mg vs. sleeve gastrectomy: a three-arm non-randomised, controlled, pilot study.Diabetes Metab2018;44:235-42

[68] Sarma S.Weight loss between glucagon-like peptide-1 receptor agonists and bariatric surgery in adults with obesity: a systematic review and meta-analysis.Obesity2022;30:2111-21

[69] Benotti PN.The sun is rising on a new era of pharmacotherapy for obesity: some words of caution.Surg Obes Relat Dis2023;19:1075-6.

[70] Schauer PR,Wolski K.Bariatric surgery versus intensive medical therapy in obese patients with diabetes.N Engl J Med2012;366:1567-76.

[71] Mingrone G,De Gaetano A.Bariatric surgery versus conventional medical therapy for type 2 diabetes.N Engl J Med2012;366:1577-85.

[72] Courcoulas AP,Eagleton JK.Surgical vs medical treatments for type 2 diabetes mellitus: a randomized clinical trial.JAMA Surg2014;149:707-15.

[73] Cummings DE,Westbrook EO.Gastric bypass surgery vs intensive lifestyle and medical intervention for type 2 diabetes: the CROSSROADS randomised controlled trial.Diabetologia2016;59:945-53 PMCID:PMC4826815

[74] Simonson DC,Foster K,Goldfine AB.Clinical and patient-centered outcomes in obese patients with type 2 diabetes 3 years after randomization to Roux-en-Y gastric bypass surgery versus intensive lifestyle management: the SLIMM-T2D study.Diabetes Care2018;41:670-9 PMCID:PMC5860843

[75] Kirwan JP,Cummings DE.Diabetes remission in the alliance of randomized trials of medicine versus metabolic surgery in type 2 diabetes (ARMMS-T2D).Diabetes Care2022;45:1574-83 PMCID:PMC9490448

[76] Mirghani H.Metabolic surgery versus usual care effects on diabetes remission: a systematic review and meta-analysis.Diabetol Metab Syndr2023;15:31 PMCID:PMC9951503

[77] Mingrone G,De Gaetano A.Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial.Lancet2015;386:964-73.

[78] Courcoulas AP,Neiberg RH.Bariatric surgery vs lifestyle intervention for diabetes treatment: 5-year outcomes from a randomized trial.J Clin Endocrinol Metab2020;105:866-76 PMCID:PMC7032894

[79] Solé T,Denneval A.Time impact on the antidiabetic effects of key bariatric surgeries: a network meta-analysis of randomized controlled trials with meta-regression.Surg Obes Relat Dis2022;18:832-45

[80] Rubino F,Eckel RH.Delegates of the 2nd Diabetes Surgery SummitMetabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations.Diabetes Care2016;39:861-77.

[81] Russel SM,Spagni G.Physiologic mechanisms of type II diabetes mellitus remission following bariatric surgery: a meta-analysis and clinical implications.J Gastrointest Surg2020;24:728-41

[82] Andreadis P,Malandris K.Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis.Diabetes Obes Metab2018;20:2255-63.

[83] Avgerinos I,Liakos A.Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis.Diabetes Obes Metab2020;22:335-45.

[84] Alhindi Y.The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: a systematic review and network meta-analysis.Contemp Clin Trials Commun2022;28:100944 PMCID:PMC9260263

[85] Karagiannis T,Liakos A.Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.Diabetologia2022;65:1251-61 PMCID:PMC9112245

[86] Blackman A,Zammit G.Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.Int J Obes2016;40:1310-9 PMCID:PMC4973216

[87] Bethel MA,Merrill P.EXSCEL Study GroupCardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.Lancet Diabetes Endocrinol2018;6:105-13

[88] Pedrosa MR,Gieremek HW.GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far?.Curr Atheroscler Rep2022;24:867-84

[89] Mahapatra MK,Sahoo BM.Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review.Pharm Res2022;39:1233-48. PMCID:PMC9159769

[90] Aminian A,Arterburn DE.Association of metabolic surgery with major adverse cardiovascular outcomes in patients with type 2 diabetes and obesity.JAMA2019;322:1271-82 PMCID:PMC6724187

[91] Ghiassi S.Safety and efficacy of bariatric and metabolic surgery.Curr Obes Rep2020;9:159-64

[92] Daigle CR,Tu C.Which postoperative complications matter most after bariatric surgery? Prioritizing quality improvement efforts to improve national outcomes.Surg Obes Relat Dis2018;14:652-7

[93] Chen G,Peng BQ,Du X.Roux-En-Y gastric bypass versus sleeve gastrectomy plus procedures for treatment of morbid obesity: systematic review and meta-analysis.Obes Surg2021;31:3303-11

[94] Alalwan AA,Park H,Brumback B.Comparative safety of sleeve gastrectomy and roux-en-y: a propensity score analysis.World J Surg2022;46:2715-24

[95] Balamurugan G,Sivagnanam ST.Comparison of efficacy and safety between Roux-en-Y gastric bypass (RYGB) vs one anastomosis gastric bypass (OAGB) vs single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S): a systematic review of bariatric and metabolic surgery.Obes Surg2023;33:2194-209.

[96] Gasmi A,Mujawdiya PK.Micronutrients deficiences in patients after bariatric surgery.Eur J Nutr2022;61:55-67

[97] Konwar M,Jaiswal SK,Ravi R.Efficacy and safety of liraglutide 3.0 mg in patients with overweight and obese with or without diabetes: a systematic review and meta-analysis.Int J Clin Pract2022;2022:1201977. PMCID:PMC9325632

[98] Amaro A,Wharton S.Efficacy and safety of semaglutide for weight management: evidence from the STEP program.Postgrad Med2022;134:5-17.

[99] Steinberg WM,Wadden TA,Jensen CB.Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight/obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development program.Diabetes Care2017;40:839-48

[100] He L,Ping F.Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials.JAMA Intern Med2022;182:513-9 PMCID:PMC8961394

[101] Woronow D,Niak A,Houstoun M.Acute cholecystitis associated with the use of glucagon-like peptide-1 receptor agonists reported to the us food and drug administration.JAMA Intern Med2022;182:1104-6. PMCID:PMC9425280

[102] Bezin J,Pénichon M.GLP-1 receptor agonists and the risk of thyroid cancer.Diabetes Care2023;46:384-90

[103] Dunleavy K. Novo Nordisk's GLP-1 drugs under review in Europe after reports flag possible suicide risks. Available from: https://www.fiercepharma.com/pharma/novo-nordisks-glp-1-drugs-under-review-europe-after-suicide-flags-raised [Last accessed on 13 Oct 2023]

[104] Castaneda D,Wander P.Risk of suicide and self-harm is increased after bariatric surgery-a systematic review and meta-analysis.Obes Surg2019;29:322-33

[105] Needham BD,Adame MD.A gut-derived metabolite alters brain activity and anxiety behaviour in mice.Nature2022;602:647-53 PMCID:PMC9170029

[106] Blackburn AN,Leggio L.The gut in the brain: the effects of bariatric surgery on alcohol consumption.Addict Biol2017;22:1540-53 PMCID:PMC5332539

[107] Spaniolas K,Celio A,Pories WJ.Postoperative follow-up after bariatric surgery: effect on weight loss.Obes Surg2016;26:900-3

[108] Reiber BMM,Bremer MJM,Bruin SC.Weight loss results and compliance with follow-up after bariatric surgery.Obes Surg2021;31:3606-14 PMCID:PMC8270808

[109] Monfared S,Selzer D.Travel distance reduces follow-up compliance but has no effect on long-term weight loss success in bariatric patients.Surg Endosc2021;35:1579-83

[110] Ziegler O,Brunaud L,Quilliot D.Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies.Diabetes Metab2009;35:544-57.

[111] Exclusive: most patients using weight-loss drugs like Wegovy stop within a year, data show. Available from: https://www.healthleadersmedia.com/pharma/exclusive-most-patients-using-weight-loss-drugs-wegovy-stop-within-year-data-show [Last accessed on 13 Oct 2023]

[112] What happens when newer weight loss meds are stopped? Available from: https://www.medscape.com/viewarticle/989988 [Last accessed on 13 Oct 2023]

[113] Pratley R,Hoff ST.PIONEER 4 investigatorsOral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.Lancet2019;394:39-50

[114] Wilding JPH,Davies M.STEP 1 Study GroupWeight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.Diabetes Obes Metab2022;24:1553-64 PMCID:PMC9542252

[115] New antiobesity drugs will benefit many. Is that bad? Available from: https://www.medscape.com/viewarticle/990128 [Last accessed on 13 Oct 2023]

[116] ICER publishes final evidence report and policy recommendations on treatments for obesity management. Available from: https://icer.org/news-insights/press-releases/strongicer-publishes-final-evidence-report-and-policy-recommendations-on-treatments-forbrobesity-managementstrong/ [Last accessed on 13 Oct 2023]

[117] Baig K,Kim DD.Medicare part D coverage of antiobesity medications-challenges and uncertainty ahead.N Engl J Med2023;388:961-3.

[118] Azuri J,Aboalhasan E,Arbel R.Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis.Obesity2023;31:1510-3.

[119] Chang SH,Colditz GA.Cost-effectiveness of bariatric surgery: should it be universally available?.Maturitas2011;69:230-8

[120] Alsumali A,Bairdain S.Cost-effectiveness analysis of bariatric surgery for morbid obesity.Obes Surg2018;28:2203-14

[121] Noparatayaporn P,Chaikledkaew U,Thakkinstian A.Incremental net monetary benefit of bariatric surgery: systematic review and meta-analysis of cost-effectiveness evidences.Obes Surg2021;31:3279-90. PMCID:PMC8175295

[122] Urva S,Loghin C.The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists.Diabetes Obes Metab2020;22:1886-91 PMCID:PMC7539915

[123] Beam WB, Hunter Guevara LR. Hunter Guevara. Are serious anesthesia risks of semaglutide and other GLP-1 agonists under-recognized? Case reports of retained solid gastric contents in patients undergoing anesthesia. Available from: https://www.apsf.org/article/are-serious-anesthesia-risks-of-semaglutide-and-other-glp-1-agonists-under-recognized/ [Last accessed on 13 Oct 2023]

[124] Blum D. People on drugs like ozempic say their ‘food noise’ has disappeared. Available from: https://www.nytimes.com/2023/06/21/well/eat/ozempic-food-noise.html [Last accessed on 13 Oct 2023]

[125] Müller TD,Tschöp MH.Anti-obesity drug discovery: advances and challenges.Nat Rev Drug Discov2022;21:201-23 PMCID:PMC8609996

[126] Praxedes DR,Macena ML,Bueno NB.Prevalence of food addiction among patients undergoing metabolic/bariatric surgery: a systematic review and meta-analysis.Obes Rev2023;24:e13529

[127] Ivezaj V,Davis J.Changes in alcohol use after metabolic and bariatric surgery: predictors and mechanisms.Curr Psychiatry Rep2019;21:85 PMCID:PMC7057935

[128] Cerón-Solano G,Romero Lozano JG,Morin JP.Bariatric surgery and alcohol and substance abuse disorder: a systematic review.Cir Esp2021;99:635-47

[129] Koball AM,Goetze RE.Addiction transfer and other behavioral changes following bariatric surgery.Surg Clin North Am2021;101:323-33

[130] Cassin S,Hawa R,Jackson T.Food addiction is associated with binge eating and psychiatric distress among post-operative bariatric surgery patients and may improve in response to cognitive behavioural therapy.Nutrients2020;12:2905 PMCID:PMC7598202

[131] Ivezaj V,Grilo CM.Food addiction and bariatric surgery: a systematic review of the literature.Obes Rev2017;18:1386-97 PMCID:PMC5691599

[132] Could semaglutide treat addiction as well as obesity? Available from: https://www.medscape.com/viewarticle/993124 [Last accessed on 13 Oct 2023]

[133] Thomsen M,Molander A,Ptito M.Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys.Psychopharmacology2019;236:603-11 PMCID:PMC6428196

[134] Klausen MK,Møller M.Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial.JCI Insight2022;7:e159863

[135] Jirapinyo P.How to incorporate bariatric training into your fellowship program.Gastroenterology2021;161:15-20

[136] Zevin B,Bonrath EM.Comprehensive simulation-enhanced training curriculum for an advanced minimally invasive procedure: a randomized controlled trial.Surg Obes Relat Dis2017;13:815-24

[137] Zerrweck C,Sánchez H,Márquez M.CMCOEMBariatric surgery in Mexico: training, practice and surgical trends.Updates Surg2021;73:1509-14

[138] Ospanov O.Training and certification for the bariatric and metabolic surgery specialization in kazakhstan.Obes Surg2023;33:368-9

[139] Blackstone R,Nguyen NT.Accreditation in metabolic and bariatric surgery: pro versus con.Surg Obes Relat Dis2014;10:198-202

[140] Clapp B,Lodeiro C.Late-term hiatal hernia after gastric bypass: an emerging problem.Surg Obes Relat Dis2020;16:471-5.

[141] SCOPE. Training&Events. Available from: https://www.worldobesity.org/training-and-events/scope [Last accessed on 13 Oct 2023]

[142] Fulton M. Obesity, stigma and discrimination. StatPearls. Treasure Island (FL): StatPearls Publishing; 2023. Available from: http://www.ncbi.nlm.nih.gov/books/NBK554571/ [Last accessed on 13 Oct 2023]

[143] Westbury S,van Rens T.Obesity stigma: causes, consequences, and potential solutions.Curr Obes Rep2023;12:10-23 PMCID:PMC9985585

[144] Garcia FK,Veen EJ,Koelen MA.Stigma toward bariatric surgery in the netherlands, france, and the united kingdom: protocol for a cross-cultural mixed methods study.JMIR Res Protoc2022;11:e36753. PMCID:PMC9100527

[145] Survodutide impresses in phase 2 weight-loss trial. Available from: https://www.medscape.com/viewarticle/993928 [Last accessed on 13 Oct 2023]

[146] American diabetes association highlights novel agent retatrutide which results in substantial weight reduction in people with obesity or type 2 diabetes during late breaking symposium. Available from: https://diabetes.org/newsroom/press-releases/2023/american-diabetes-association-highlights-novel-agent-retatrutide-results-substantial-weight-reduction-people-with-obesity-type-2-diabetes-during-late-breaking-symposium [Last accessed on 13 Oct 2023]

[147] Triple agonist retatrutide hits new weight-loss highs. Available from: https://www.medscape.com/viewarticle/993714 [Last accessed on 13 Oct 2023]

[148] New oral GLP-1 agonist for obesity, type 2 diabetes. Available from: https://www.medscape.com/viewarticle/993667 [Last accessed on 13 Oct 2023]

[149] Wharton S,Connery L.GZGI InvestigatorsDaily oral GLP-1 receptor agonist orforglipron for adults with obesity.N Engl J Med2023;389:877-88.

[150] Specchia ML,Carini E.The impact of tumor board on cancer care: evidence from an umbrella review.BMC Health Serv Res2020;20:73. PMCID:PMC6995197

[151] Heald RJ.The 'holy plane' of rectal surgery.J R Soc Med1988;81:503-8. PMCID:PMC1291757

[152] Knol J.Total mesorectal excision technique-past, present, and future.Clin Colon Rectal Surg2020;33:134-43 PMCID:PMC7188504

[153] Canning KL,Wharton S,Kuk JL.Edmonton obesity staging system prevalence and association with weight loss in a publicly funded referral-based obesity clinic.J Obes2015;2015:619734 PMCID:PMC4427774

[154] Wharton S,Luszczynski M,Christensen RAG.Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery.Clin Obes2019;9:e12323 PMCID:PMC6771702

[155] Lautenbach A,Huber TB.The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery-a retrospective analysis.Obes Surg2022;32:3280-8. PMCID:PMC9532334

[156] Muratori F,Di Sacco G,Pellegrino D.Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery.Eat Weight Disord2022;27:2775-81 PMCID:PMC9556416

[157] Jensen AB,Aczél S.Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study.Obes Surg2023;33:1017-25. PMCID:PMC9918402